Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience

Clinical Therapeutics

Volumn 25, Issue 3, 2003, Pages 799-816

  Massi Benedetti, Massimo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Glimepiride; Sulfonylureas; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ADULT; AGED; BODY WEIGHT DISORDER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART INFARCTION PREVENTION; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 0037363784     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80109-1     Document Type: Review

References (60)

1. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989;321:337-343.
2. Porte D Jr, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: Potential mechanisms. Diabetes. 2001;50(Suppl 1):S160-S163.
3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-794.
4. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.
5. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
8. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am. 1997;26:511-522.
9. Amaryl [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals Inc; 2000.
10. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512-1517.
11. Kramer W, Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res. 1996;28:464-468.
12. Muller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta. 1994;1191:267-277.
13. Kramer W, Muller G, Girbig F, et al. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochim Biophys Acta. 1994;1191:278-290.
14. Campbell RK. Glimepiride: Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother. 1998;32:1044-1052.
15. Shukla UA, Sha X, Lehr KH, et al. Single dose and steady-state pharmacokinetics of glimepiride (G), a new oral sulfonylurea, in patients with non-insulin-dependent diabetes mellitus (NIDDM). Pharm Res. 1994;11:S368. Abstract PPDM 8144.
16. Lehr KH, Damm P. Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. J Chromatogr. 1990;526:497-505.
17. Goldberg RB, Holvey SM, Schneider J, for the Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996;19:849-856.
18. Massi-Benedetti M, Faure E. Glimepiride administered once daily is equally effective as twice daily gliclazide for controlling blood glucose levels in patients with type 2 diabetes. Diabetes. 2001;50(Suppl 2):A442. Abstract 1845-PO.
19. Clark CM, Goldberg RB. Glimepiride dosing and efficacy: Results of placebo-controlled, dose-regimen, and active-controlled trials. In: Whitehouse F, Gavin J, eds. Postgraduate Medicine Special Report: Therapeutic Strategies for Managing NIDDM. Minneapolis: McGraw-Hill Healthcare Information Group; 1997:45-56.
20. Sonnenberg GE, Garg DC, Weidler DJ, et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1997;31:671-676.
21. Schneider J. An overview of the safety and tolerance of glimepiride. Horm Metab Res. 1996;28:413-418.
22. Del Guerra S, Marselli L, Lupi R, et al. Effects of chronic exposure of isolated human islets to glimepiride, glibenclamide or chlorpropamide. Diabetologia. 2001;44(Suppl 1):A136. Abstract 520.
23. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157:1681-1686.
24. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care. 2002;25:2109-2110.
25. Dills DG, Schneider J, for the Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res. 1996;28:426-429.
26. Rosskamp R, Wernicke-Panten K, Draeger E. Clinical profile of the novel sulphonyl-urea glimepiride. Diabetes Res Clin Pract. 1996;31(Suppl):S33-S42.
27. Tsumura K. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res Clin Pract. 1995;28(Suppl): S147-S149.
28. Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res. 1996;28:451-455.
29. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-88.
30. Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: A meta-analysis. Diabetes Res Clin Pract. 2000;50(Suppl 2):S47. Abstract P251.
31. Herrmann M, Knirsch W, Krauth R. Glimepiride (Amaryl): Results of a non-interventional study in Germany. Diabetes Res Clin Pract. 2000;50(Suppl):S346. Abstract 1374.
32. Lechleitner M, Weitgasser R. Improvement in glycaemic control and weight gain in patients with type 2 diabetes mellitus during long-term treatment with glimepiride. Acta Med Austriaca. 1999;26(Suppl 50):S16. Abstract.
33. Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol Med. 2000;6:907-933.
34. Overkamp D, Volk A, Maerker E, et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care. 2002;25:2065-2073.
35. Del Guerra S, Parentini C, Bracci C, et al. Insulin release from isolated, human islets after acute or prolonged exposure to glimepiride. Acta Diabetol. 2000;37:139-141.
36. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789-830.
37. + channels in cardiac muscle. Nature. 1983;305:147-148.
38. Smits P, Bijlstra PJ, Russel FG, et al. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Pract. 1996;31(Suppl):S55-S59.
39. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K (ATP) channels. Br J Pharmacol. 2001;133:193-199.
40. Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel, sulfonylurea does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111-3116.
41. Brady PA, Terzic A. The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol. 1998;31:950-956.
42. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999;20:439-446.
43. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res. 1991;69:571-581.
44. Koltai MZ. Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart. Diabetes Res Clin Pract. 1996;31(Suppl):S15-S20.
45. El-Reyani NE, Bozdogan O, Baczko I, et al. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. Eur J Pharmacol. 1999;365:187-192.
46. Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res. 1996;28:496-507.
47. Pogatsa G. What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents? Diabetes Res Clin Pract. 1996;31(Suppl):S27-S31.
48. Vegh A, Papp JG. Haemodynamic and other effects of sulphonylurea drugs on the heart. Diabetes Res Clin Pract. 1996;31(Suppl):S43-S53.
49. Rosenstock J. Management of type 2 diabetes mellitus in the elderly: Special considerations. Drugs Aging. 2001;18:31-44.
50. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39:1617-1624.
51. Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res. 1996;28:434-439.
52. Dornhorst A. Abnormalities of beta cell function in the development and progression of type 2 diabetes. Pract Diabetes Int. 2001;18:S4-S6.
53. Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001;18:828-834.
54. Riddle MC. Combined therapy with a sulfonylurea plus evening insulin: Safe, reliable, and becoming routine. Horm Metab Res. 1996;28:430-433.
55. Riddle M, Schneider J, for the Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care. 1998;21:1052-1057.
56. Rosenstock J. Combination glimepiride-insulin 70/30 therapy for NIDDM. In: Whitehouse F, Gavin J, eds. Postgraduate Medicine Special Report: Therapeutic Strategies for Managing NIDDM. Minneapolis: McGraw-Hill Healthcare Information Group; 1997:26-32.
57. Scholz G, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice. A non-interventional observational cohort study. Clin Drug Invest. 2001;21:597-604.
58. Martin S, Scherbaum WA, Kolb W. Analysis of the impact of oral antidiabetic drugs on development of body weight by a retrolective trial, a new form of non-biased retrospective clinical study design. Diabetes. 2002;51(Suppl 2):A107. Abstract 433.
59. 1c without weight gain in patients with type 2 diabetes treated with glim, both alone and in combination therapies. Diabetes. 2002;51(Suppl 1):A606. Abstract 2514.
60. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17:467-473.